| Literature DB >> 30464636 |
Hongjiang Wu1,2, Eric Sh Lau3, Alice Ps Kong2,4, Ronald Cw Ma2,4, Risa Ozaki4, Kitty Kt Cheung4, Elaine Chow4, Chiu Chi Tsang5, Kam Piu Lau6, Eric Mt Hui7, Wing Yee So8, Danijela Gasevic1,9, Sarah H Wild1, Juliana Cn Chan2,3,4, Andrea Luk2,3,4.
Abstract
PURPOSE: The aim of this study was to describe the association between educational level and incident cardiovascular disease (CVD) and all-cause mortality in Hong Kong Chinese patients with type 2 diabetes. PATIENTS AND METHODS: We included 12,634 patients with type 2 diabetes who were enrolled into the Joint Asia Diabetes Evaluation Program between June 1, 2007, and June 30, 2017. We classified patients' educational level into the following three groups: ≤6 years, 6-13 years, and >13 years. Incident CVD events were identified using hospital discharge diagnoses. Death was identified from Hong Kong Death Register. We estimated HRs for incident CVD and all-cause mortality using Cox regression models.Entities:
Keywords: all-cause mortality; cardiovascular disease; diabetes; educational level; socioeconomic status
Year: 2018 PMID: 30464636 PMCID: PMC6208565 DOI: 10.2147/CLEP.S177437
Source DB: PubMed Journal: Clin Epidemiol ISSN: 1179-1349 Impact factor: 4.790
Characteristics of patients (n=12,643) according to educational level
| Variables | Education (years of education) | ||
|---|---|---|---|
| ≤6 (n=5,232) | 6–13 (n=5,974) | >13 (n=1,428) | |
| Age at the diagnosis of diabetes (years) | 54.2 (11.0) | 48.7 (10.1) | 48.7 (10.3) |
| Age at enrollment (years) | 63.6 (9.4) | 56.2 (9.2) | 55.7 (10.1) |
| Women | 3,265 (62.4) | 2,360 (39.5) | 398 (27.9) |
| Diabetes duration (years), median (IQR) | 8.0 (3.0–14.0) | 5.5 (2.0–12.0) | 5.0 (1.0–11.0) |
| Family history of diabetes | 2,577 (49.3) | 3,856 (64.5) | 981 (68.7) |
| Health-related behaviors | |||
| Current smoking | 536 (10.2) | 780 (13.1) | 125 (8.8) |
| Current use of alcohol | 1,268 (24.2) | 2,118 (35.5) | 560 (39.2) |
| Regular physical activity (≥3 times/week) | 2,743 (52.4) | 2,588 (43.3) | 629 (44.0) |
| Good adherence to balanced diet | 2,819 (53.9) | 3,042 (50.9) | 729 (51.1) |
| Treatment | |||
| Regular medical follow-up (≥1 time/year) | 5,104 (97.6) | 5,717 (95.7) | 1,338 (93.7) |
| Diabetes education | 3,951 (75.5) | 4,341 (72.7) | 964 (67.5) |
| Oral antidiabetic drugs | 4,529 (86.6) | 5,104 (85.4) | 1,202 (84.2) |
| Insulin | 1,270 (24.3) | 1,220 (20.4) | 261 (18.3) |
| Antihypertensive drugs | 3,410 (65.2) | 3,289 (55.1) | 775 (54.3) |
| Lipid-lowering drugs | 2,440 (46.6) | 2,566 (43.0) | 643 (45.0) |
| Baseline prevalent comorbidities | |||
| Diabetic retinopathy | 1,520 (29.1) | 1,460 (24.4) | 259 (18.1) |
| Sensory neuropathy | 302 (5.8) | 198 (3.3) | 42 (2.9) |
| Chronic kidney disease | 1,161 (22.2) | 762 (12.8) | 157 (11.0) |
| End-stage renal disease | 63 (1.2) | 57 (1.0) | 15 (1.1) |
| Albuminuria | 2,121 (40.5) | 2,019 (33.8) | 416 (29.1) |
| Cancer | 375 (7.2) | 310 (5.2) | 68 (4.8) |
| Metabolic risk factors | |||
| BMI (kg/m2) | 25.7 (4.2) | 25.9 (4.3) | 26.2 (4.4) |
| Waist circumference (men) (cm) | 90.9 (10.4) | 91.0 (10.6) | 92.0 (10.6) |
| Waist circumference (women) (cm) | 86.8 (10.7) | 85.9 (11.0) | 85.5 (11.2) |
| Waist-to-hip ratio (men) | 0.96 (0.07) | 0.95 (0.06) | 0.94 (0.06) |
| Waist-to-hip ratio (women) | 0.91 (0.07) | 0.89 (0.07) | 0.88 (0.07) |
| SBP (mmHg) | 137.5 (18.7) | 132.6 (17.6) | 130.3 (16.6) |
| DBP (mmHg) | 77.2 (10.3) | 78.9 (10.6) | 78.6 (10.1) |
| Hypertension | 4,366 (83.4) | 4,552 (76.2) | 1,064 (74.5) |
| HbA1c% (mmol/mol) | 7.56 (59.1) | 7.53 (58.8) | 7.36 (56.9) |
| Fasting plasma glucose (mmol/L) | 7.82 (2.55) | 7.85 (2.51) | 7.77 (2.41) |
| HDL cholesterol (mmol/L) | 1.36 (0.37) | 1.31 (0.35) | 1.28 (0.36) |
| LDL cholesterol (mmol/L) | 2.68 (0.84) | 2.69 (0.88) | 2.64 (0.86) |
| Triglycerides (mmol/L) | 1.50 (0.90) | 1.55 (1.01) | 1.60 (0.99) |
Notes: Data are mean (SD) or n (%), unless otherwise indicated.
Hypertension defined as SBP ≥130 or DBP ≥80 or taking antihypertensive drugs.
Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Duration of follow-up and CVD and all-cause mortality rates according to educational level (n=12,634)
| Events | Education (years of education) | ||
|---|---|---|---|
| ≤6 (n=5,232) | 6–13 (n=5,974) | >13 (n=1,428) | |
| Incident CVD | |||
| Number of events | 502 | 374 | 78 |
| Number of person-years | 30,173 | 35,141 | 8,420 |
| Crude event rate (number/1,000 person-years) | 16.6 | 10.6 | 9.3 |
| Age- and sex-standardized | 17.4 | 10.8 | 8.9 |
| All-cause mortality | |||
| Number of events | 487 | 288 | 58 |
| Number of person-years | 31,534 | 36,175 | 8,691 |
| Crude event rate (number/1,000 person-years) | 15.4 | 8.0 | 6.7 |
| Age- and sex-standardized | 14.4 | 8.1 | 7.4 |
Notes:
Total population included in the analysis by age at diabetes diagnosis (quartiles) and sex is used as the standard population.
Abbreviation: CVD, cardiovascular disease.
Figure 1Kaplan–Meier curves for incident CVD (A) and all-cause mortality (B) by educational level.
Abbreviation: CVD, cardiovascular disease.
HRs for incident CVD and all-cause mortality according to educational level in models including different covariates (n=12,634)
| Cox models | Education (years of education) | |||
|---|---|---|---|---|
| ≤6 (reference) | 6–13 | >13 | ||
| HR | HR (95% CI) | HR (95% CI) | ||
| Incident CVD | ||||
| Model 1 | 1 | 0.63 (0.55, 0.73) | 0.53 (0.41, 0.67) | <0.001 |
| Model 2 | 1 | 0.87 (0.75, 1.00) | 0.73 (0.57, 0.94) | 0.006 |
| Model 3 | 1 | 0.90 (0.78, 1.04) | 0.79 (0.62, 1.01) | 0.041 |
| Model 4 | 1 | 0.88 (0.76, 1.02) | 0.75 (0.59, 0.97) | 0.015 |
| Model 5 | 1 | 0.90 (0.78, 1.05) | 0.80 (0.62, 1.03) | 0.052 |
| Model 6 | 1 | 0.92 (0.80, 1.07) | 0.84 (0.65, 1.07) | 0.13 |
| Model 7 | 1 | 0.97 (0.83, 1.12) | 0.92 (0.71, 1.18) | 0.48 |
| All-cause mortality | ||||
| Model 1 | 1 | 0.61 (0.52, 0.71) | 0.49 (0.37, 0.65) | <0.001 |
| Model 2 | 1 | 0.89 (0.76, 1.05) | 0.71 (0.54, 0.94) | 0.014 |
| Model 3 | 1 | 0.92 (0.79, 1.08) | 0.75 (0.57, 0.99) | 0.051 |
| Model 4 | 1 | 0.93 (0.79, 1.08) | 0.75 (0.57, 0.99) | 0.050 |
| Model 5 | 1 | 0.94 (0.81, 1.11) | 0.78 (0.59, 1.04) | 0.11 |
| Model 6 | 1 | 0.93 (0.79, 1.09) | 0.79 (0.59, 1.05) | 0.10 |
| Model 7 | 1 | 0.98 (0.84, 1.15) | 0.88 (0.66, 1.17) | 0.46 |
Notes: Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, diabetes duration, and family history of diabetes. Model 3: model 2+ health behaviors (including smoking, use of alcohol, physical activity, and adherence to balanced diet). Model 4: model 2+ treatment (including regular medical follow-up, diabetes education, oral antidiabetic drugs, use of insulin, antihypertensive drugs, and lipid regulating drugs). Model 5: model 2+ baseline prevalent comorbidities (including cancer, albuminuria, diabetic retinopathy, sensory neuropathy, end-stage renal disease, and chronic kidney disease). Model 6: model 2+ baseline metabolic risk factors (including body mass index, waist-to-hip ratio, SBP, DBP, hemoglobin A1c, fasting blood glucose, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides). Model 7: adjusted for all variables listed above.
Abbreviation: CVD, cardiovascular disease.
Characteristics of patients with (n=12,634) and without (n=14,014) complete data: Hong Kong, 2007–2017
| Variables | Participants with complete data (n=12,634) | Participants without complete data (n=14,014) |
|---|---|---|
| Age at diagnosis of diabetes (years) | 50.9 (10.9) | 50.9 (10.9) |
| Age at enrollment (years) | 59.2 (10.1) | 58.2 (11.4) |
| Women | 6,023 (47.7) | 6,700 (47.8) |
| Diabetes duration (years), median (IQR) | 6.0 (2–13) | 6.0 (2–13) |
| Educational level | ||
| ≤6 years | 5,232 (41.4) | 5,603 (40.1) |
| >6 and ≤13 years | 5,974 (47.3) | 6,661 (47.7) |
| 3 years | 1,428 (11.3) | 1,698 (12.2) |
| Family history of diabetes | 7,414 (58.7) | 8,207 (58.6) |
| Health-related behaviors | ||
| Current smoking | 1,441 (11.4) | 1,663 (11.9) |
| Current use of alcohol | 3,946 (31.2) | 4,405 (31.5) |
| Regular physical activity (≥3 times/week) | 5,960 (47.2) | 6,386 (45.7) |
| Good adherence to balanced diet | 6,590 (52.2) | 7,274 (52.0) |
| Treatment | ||
| Regular medical follow-up (≥1 time/year) | 12,159 (96.2) | 13,380 (95.6) |
| Diabetes education | 9,256 (73.3) | 10,288 (73.6) |
| Oral antidiabetic drugs | 10,835 (85.8) | 11,854 (84.6) |
| Insulin | 2,751 (21.8) | 3,092 (22.1) |
| Antihypertensive drugs | 7,474 (59.2) | 8,081 (57.7) |
| Lipid-lowering drugs | 5,649 (44.7) | 6,079 (43.4) |
| Baseline prevalent comorbidities | ||
| Diabetic retinopathy | 3,239 (25.6) | 3,537 (25.4) |
| Sensory neuropathy | 542 (4.3) | 583 (4.2) |
| Chronic kidney disease | 2,080 (16.5) | 2,289 (16.3) |
| End-stage renal disease | 135 (1.1) | 167 (1.2) |
| Albuminuria | 4,556 (36.1) | 4,974 (36.2) |
| Cancer | 753 (6.0) | 815 (5.8) |
| Metabolic risk factors | ||
| BMI (kg/m2) | 25.9 (4.2) | 26.0 (4.4) |
| Waist circumference (men) (cm) | 91.1 (10.5) | 91.2 (10.7) |
| Waist circumference (women) (cm) | 86.4 (10.9) | 86.4 (11.1) |
| Waist-to-hip ratio (men) | 0.95 (0.06) | 0.95 (0.07) |
| Waist-to-hip ratio (women) | 0.90 (0.07) | 0.90 (0.07) |
| SBP (mmHg) | 134.4 (18.1) | 134.0 (18.2) |
| DBP (mmHg) | 78.2 (10.4) | 78.1 (10.5) |
| Hypertension | 9,982 (79.0) | 10,900 (77.8) |
| HbA1c% (mmol/mol) | 7.53 (58.8) | 7.55 (59.0) |
| Fasting plasma glucose (mmol/L) | 7.83 (2.52) | 7.86 (2.60) |
| HDL cholesterol (mmol/L) | 1.33 (0.36) | 1.32 (0.37) |
| LDL cholesterol (mmol/L) | 2.68 (0.86) | 2.69 (0.87) |
| Triglycerides (mmol/L) | 1.54 (0.96) | 1.63 (1.46) |
Notes: Data are mean (SD) or n (%), unless otherwise indicated. Missing data for participants without complete data were 667 for age at the diagnosis of diabetes, 1 for age at enrollment, 667 for diabetes duration, 4 for smoking, 8 for the use of alcohol, 42 for regular physical activity, 30 for good adherence to balanced diet, 12 for regular medical follow-up, 39 for diabetes education, 12 for antihypertensive drugs, 10 for lipid lowering drugs, 104 for diabetic retinopathy, 4 for sensory neuropathy, 280 for albuminuria, 24 for BMI, 25 for waist circumference, 33 for waist-to-hip ratio, 6 for SBP, 6 for DBP, 5 for hypertension, 25 for HbA1c, 57 for fasting plasma glucose, 62 for HDL cholesterol, 265 for LDL cholesterol, 53 for triglycerides.
Hypertension defined as SBP ≥130 or DBP ≥80 or taking antihypertensive drugs.
Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Subdistribution HRs for incident CVD according to educational level (n=12,634): Hong Kong, 2007–2017
| Subdistribution HRs | Education (years of education) | ||
|---|---|---|---|
| 6 (reference) | ≤ 6–13 | >13 | |
| sHR | sHR (95% CI) | sHR (95% CI) | |
| Model 1 | 1 | 0.64 (0.55, 0.74) | 0.53 (0.42, 0.68) |
| Model 2 | 1 | 0.86 (0.75, 1.01) | 0.74 (0.58, 0.94) |
| Model 3 | 1 | 0.90 (0.77, 1.04) | 0.79 (0.62, 1.02) |
| Model 4 | 1 | 0.88 (0.76, 1.03) | 0.76 (0.59, 0.97) |
| Model 5 | 1 | 0.90 (0.78, 1.05) | 0.80 (0.62, 1.03) |
| Model 6 | 1 | 0.92 (0.79, 1.07) | 0.83 (0.65, 1.07) |
| Model 7 | 1 | 0.96 (0.82, 1.11) | 0.91 (0.71, 1.17) |
Notes: Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, diabetes duration, and family history of diabetes. Model 3: model 2+ health behaviors (including smoking, use of alcohol, physical activity, and adherence to balanced diet). Model 4: model 2+ treatment (including regular medical follow-up, diabetes education, oral antidiabetic drugs, use of insulin, antihypertensive drugs, and lipid-regulating drugs). Model 5: model 2+ baseline prevalent comorbidities (including cancer, albuminuria, diabetic retinopathy, sensory neuropathy, end-stage renal disease, and chronic kidney disease). Model 6: model 2+ baseline metabolic risk factors (body mass index, waist-to-hip ratio, SBP, DBP, hemoglobin A1c, fasting blood glucose, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides). Model 7: adjusted for all variables listed above.
Abbreviations: CVD, cardiovascular disease; sHR, subdistribution HR.
HRs for incident CVD and all-cause mortality according to educational level in strata for age, sex, and diabetes duration: Hong Kong, 2007–2017
| Subgroups | Education (years of education) | |||
|---|---|---|---|---|
| ≤6 (reference) | 6–13 | >13 | ||
| HR | HR (95% CI) | HR (95% CI) | ||
| Incident CVD | ||||
| Age at diagnosis of diabetes (years) | ||||
| <50 | 1 | 0.84 (0.67, 1.05) | 0.62 (0.42, 0.91) | 0.19 |
| ≥50 | 1 | 0.69 (0.57, 0.84) | 0.68 (0.50, 0.95) | |
| Sex | ||||
| Men | 1 | 0.81 (0.67, 0.97) | 0.71 (0.54, 0.95) | 0.78 |
| Women | 1 | 1.00 (0.79, 1.27) | 0.69 (0.40, 1.22) | |
| Diabetes duration (years) | ||||
| <7 | 1 | 0.82 (0.64, 1.04) | 0.64 (0.42, 0.97) | 0.89 |
| ≥7 | 1 | 0.73 (0.61, 0.87) | 0.65 (0.47, 0.88) | |
| All-cause mortality | ||||
| Age at diagnosis of diabetes (years) | ||||
| <50 | 1 | 0.85 (0.64, 1.12) | 0.35 (0.18, 0.66) | 0.008 |
| ≥50 | 1 | 0.63 (0.52, 0.77) | 0.69 (0.51, 0.94) | |
| Sex | ||||
| Men | 1 | 0.93 (0.76, 1.13) | 0.73 (0.53, 1.01) | 0.41 |
| Women | 1 | 0.85 (0.64, 1.12) | 0.65 (0.35, 1.24) | |
| Diabetes duration (years) | ||||
| <7 | 1 | 0.81 (0.63, 1.06) | 0.67 (0.43, 1.06) | 0.96 |
| ≥7 | 1 | 0.73 (0.60, 0.89) | 0.59 (0.41, 0.84) | |
Note: All models were adjusted for age at the diagnosis of diabetes, sex (as appropriate), diabetes duration, and family history of diabetes.
Abbreviation: CVD, cardiovascular disease.